Table 2. Colorectal cancer-specific and overall survival according to statin use, p53 and HMGCR immunohistochemistry, and KRAS mutation status.

	Colorectal cancer-specific survival					Overall survival
Characteristic	No. of CRC deaths/at risk	Unadjusted HR (95% CI)	P-value	Adjusted HR (95% CI)a	P-value	No. of deaths/at risk	Unadjusted HR (95% CI)	P-value	Adjusted HR (95% CI)b	P-value
All participants
Statin non-user	163/508	1 (Reference)		1 (Reference)		227/508	1 (Reference)		1 (Reference)
Statin user	49/172	0.90 (0.65–1.24)	0.51	0.91 (0.64–1.28)	0.58	72/172	0.96 (0.74–1.25)	0.76	0.83 (0.61–1.12)	0.22
Patterns of p53 immunostaining
Normal	59/242	1 (Reference)		1 (Reference)		97/242	1 (Reference)		1 (Reference)
Aberrant	128/361	1.53 (1.13–2.09)	0.007	1.38 (0.97–1.95)	0.07	173/361	1.27 (0.99–1.62)	0.06	1.13 (0.85–1.49)	0.41
HMGCR tertiles
1 (lowest)	72/197	1 (Reference)		1 (Reference)		102/197	1 (Reference)		1 (Reference)
2	61/200	0.84 (0.60–1.19)	0.33	0.84 (0.58–1.21)	0.35	91/200	0.91 (0.69–1.21)	0.53	0.89 (0.66–1.21)	0.47
3 (highest	55/206	0.73 (0.51–1.04)	0.08	0.76 (0.51–1.14)	0.18	78/206	0.76 (0.56–1.02)	0.07	0.77 (0.55–1.07)	0.12
KRAS
Wild-type	109/365	1 (Reference)		1 (Reference)		156/365	1 (Reference)		1 (Reference)
Mutated	76/229	1.16 (0.86–1.55)	0.33	1.12 (0.82–1.53)	0.49	111/229	1.18 (0.92–1.51)	0.18	1.14 (0.88–1.48)	0.32

Abbreviations: CI=confidence interval; CRC=colorectal cancer; ECOG=Eastern Cooperative Oncology Group; HR=hazard ratio; MSI=microsatellite instability.

^aMultivariable model adjusted for age, gender, year of diagnosis, grade, MSI status, ECOG performance status, family history of colorectal cancer, adjuvant chemotherapy use, stage, and aspirin use.

^bMultivariable model adjusted for all variables in footnote a and also adjusted for Charlson Comorbidity Index score.